Turner Syndrome in Adults: Contemporary Management Strategies

Dr Neeraj Manikath , claude.ai

Abstract

Turner syndrome (TS), affecting approximately 1 in 2,000-2,500 live female births, represents one of the most common sex chromosome abnormalities encountered in clinical practice. While traditionally viewed as a pediatric condition, the expanding lifespan of individuals with TS necessitates that internists develop comprehensive expertise in managing the multisystem manifestations of this condition. This review synthesizes current evidence on the pathophysiology, screening protocols, and contemporary management strategies for TS in adult patients, with emphasis on cardiovascular, endocrine, reproductive, and psychosocial complications. We highlight emerging therapeutic approaches and provide practical clinical pearls for optimizing outcomes in this unique patient population.

Introduction

Turner syndrome results from complete or partial absence of one X chromosome, with approximately 50% of cases involving 45,X karyotype and the remainder demonstrating mosaicism or structural X chromosome abnormalities. The phenotypic spectrum varies considerably, ranging from subtle features in mosaic individuals to classic manifestations including short stature, gonadal dysgenesis, characteristic dysmorphic features, and multiple organ system involvement.

The transition of care from pediatric to adult medicine represents a critical juncture where patients are particularly vulnerable to care fragmentation. Internal medicine physicians increasingly serve as primary caregivers for adult women with TS, necessitating familiarity with the condition's natural history and evidence-based management strategies.

Genetic and Molecular Considerations

Karyotypic Heterogeneity

The genetic basis of TS encompasses several distinct patterns:

Monosomy X (45,X): Present in approximately 50-60% of cases, associated with more severe phenotype
Mosaicism: Accounts for 15-25% of cases (e.g., 45,X/46,XX), generally correlates with milder manifestations
Structural abnormalities: Including isochromosome Xq, ring chromosome X, or deletions, comprising 20-30% of cases
Y chromosome material: Identified in 5-10% of patients, carrying significant implications for gonadoblastoma risk

Clinical Pearl: Karyotyping should include analysis of at least 30 cells from peripheral blood. In patients with milder phenotypes or atypical presentations, consider analyzing multiple tissue types (blood, skin fibroblasts) to detect low-level mosaicism that may influence prognosis and management decisions.

Haploinsufficiency and Phenotypic Expression

The SHOX gene (short stature homeobox-containing gene) on the pseudoautosomal region of the X chromosome plays a crucial role in skeletal development. Its haploinsufficiency contributes significantly to the short stature and skeletal abnormalities observed in TS. Other genes on the X chromosome that escape X-inactivation likely contribute to additional phenotypic features, though the precise mechanisms remain under investigation.

Cardiovascular Manifestations: The Leading Cause of Excess Mortality

Cardiovascular disease represents the most significant contributor to the three-fold increased mortality risk in TS, accounting for up to 40% of deaths in adult women with this condition.

Congenital Cardiovascular Anomalies

Prevalence and Spectrum: Congenital heart disease occurs in 30-50% of individuals with TS, with bicuspid aortic valve (BAV) being the most common anomaly (15-30%), followed by coarctation of the aorta (10-15%), and partial anomalous pulmonary venous return (13%).

Aortic Dissection Risk: Women with TS face a 100-fold increased risk of aortic dissection compared to the general population, with peak incidence in the third and fourth decades. Risk factors include:

BAV
Coarctation of the aorta (repaired or unrepaired)
Aortic size index (ASI) >2.0 cm/m²
Hypertension
Pregnancy

Clinical Pearl: Calculate the aortic size index (ASI = aortic diameter in cm/body surface area in m²) rather than relying on absolute measurements. Values >2.5 cm/m² warrant particularly close surveillance, and values >2.5-3.0 cm/m² should prompt consideration of prophylactic surgical intervention, especially if other risk factors are present.

Acquired Cardiovascular Disease

Hypertension affects 40-60% of adults with TS, often developing in childhood or adolescence. The etiology is multifactorial, involving renal anomalies, coarctation, endothelial dysfunction, and increased arterial stiffness.

Coronary artery disease occurs prematurely in TS, likely related to accelerated atherosclerosis from metabolic syndrome components. A Danish nationwide cohort study demonstrated a 2.5-fold increased risk of ischemic heart disease in women with TS.

Contemporary Cardiovascular Screening and Management

Initial Assessment:

Comprehensive echocardiography with specific attention to aortic root dimensions at multiple levels (annulus, sinuses of Valsalva, sinotubular junction, ascending aorta)
Cardiac MRI or CT angiography for complete assessment of the aorta and great vessels, particularly to evaluate the aortic arch and descending aorta beyond echocardiographic windows
24-hour ambulatory blood pressure monitoring to detect masked hypertension and abnormal nocturnal dipping patterns

Surveillance Protocol:

Annual cardiovascular examination with blood pressure monitoring
Echocardiography every 3-5 years if normal initial imaging and no risk factors
Annual imaging if BAV, dilated aorta (ASI >2.0 cm/m²), or other abnormalities detected
Cardiac MRI/CT every 5-10 years for comprehensive aortic surveillance

Management Strategies:

Hypertension Management: Target blood pressure <130/80 mmHg, with beta-blockers or ACE inhibitors/ARBs preferred as first-line agents due to potential aortic protective effects. The ATENA study suggested that losartan may reduce aortic growth rate in TS, though definitive evidence remains limited.

Aortic Surveillance: Serial imaging to detect progressive dilatation. Prophylactic aortic root replacement considered when ASI exceeds 2.5 cm/m² in the presence of additional risk factors or with documented rapid progression (>3 mm/year).

The "Oyster": Don't be falsely reassured by normal echocardiography. Aortic dissection can occur with normal aortic dimensions in TS, particularly at the aortic isthmus. Always ensure comprehensive imaging of the entire aorta with MRI or CT, and maintain lifelong surveillance regardless of initial findings.

Endocrine Complications

Growth and Stature

Short stature, present in >95% of untreated individuals, results from SHOX haploinsufficiency, intrauterine growth restriction, and often, growth hormone deficiency or resistance. Untreated adult height averages 143-145 cm.

Growth hormone therapy initiated in childhood can improve final adult height by 5-10 cm. For adults, growth hormone is generally not indicated unless documented growth hormone deficiency exists.

Gonadal Function and Hormone Replacement

Primary ovarian insufficiency (POI) affects >90% of women with TS, typically presenting as primary amenorrhea or early menopause. Spontaneous puberty occurs in 15-30%, more commonly in mosaic karyotypes, but premature ovarian failure usually supervenes.

Contemporary Hormone Replacement Therapy (HRT):

The optimal approach to HRT in TS remains an area of active investigation, but current consensus emphasizes:

Initiation timing: Begin at the age of normal puberty (11-12 years) to optimize bone health, metabolic parameters, and psychosexual development
Estrogen dosing: Start with low-dose 17β-estradiol (transdermal preferred to minimize hepatic effects and venous thromboembolism risk), gradually increasing over 2-3 years to mimic physiological puberty
Progestogen addition: After 2 years of estrogen therapy or once breakthrough bleeding occurs
Duration: Continue until at least the average age of menopause (50-51 years) unless contraindications develop

Clinical Hack: Use transdermal estradiol preparations whenever possible in TS. They provide more physiological hormone levels, bypass hepatic first-pass metabolism (reducing effects on clotting factors, triglycerides, and CRP), and may confer lower cardiovascular and thromboembolic risk—particularly important given the baseline elevated cardiovascular risk in this population.

Recent data suggest that women with TS on HRT have better cardiovascular risk profiles and bone density than those not receiving therapy, emphasizing the importance of adherence.

Metabolic Complications

Type 2 diabetes mellitus occurs in 10-35% of adults with TS, representing a 2-4 fold increased risk compared to age-matched controls. The mechanism involves insulin resistance, potentially related to haploinsufficiency of X-chromosome genes involved in glucose metabolism, adipose distribution abnormalities, and growth hormone treatment effects.

Dyslipidemia affects up to 50% of adults with TS, characterized by elevated LDL cholesterol, triglycerides, and reduced HDL cholesterol. Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized, with prevalence estimates ranging from 20-80% depending on diagnostic criteria.

Management Approach:

Annual screening for diabetes with fasting glucose and HbA1c, consider oral glucose tolerance testing given increased risk of impaired glucose tolerance
Lipid panel annually; treat according to standard guidelines with consideration of elevated baseline cardiovascular risk
Screen for NAFLD with hepatic ultrasound and transient elastography; manage with lifestyle modification and consider pharmacotherapy for progressive disease
Maintain healthy body weight through diet and exercise, as obesity significantly amplifies metabolic complications

Thyroid Dysfunction

Autoimmune thyroid disease affects 15-30% of women with TS, predominantly hypothyroidism secondary to Hashimoto thyroiditis. The risk increases with age.

Annual screening with TSH and thyroid peroxidase antibodies is recommended. Standard thyroid hormone replacement protocols apply when indicated.

Bone Health

Osteoporosis and osteopenia affect 30-50% of adults with TS, resulting from multiple factors:

Estrogen deficiency
Vitamin D deficiency
Physical inactivity
Possible intrinsic skeletal defects related to haploinsufficiency

Optimization Strategy:

DEXA scan at transition to adult care, then every 3-5 years if normal, more frequently if abnormal
Ensure adequate vitamin D (target 25-OH vitamin D >30 ng/mL) and calcium intake (1,200-1,500 mg daily)
Optimize HRT compliance
Weight-bearing exercise program
Consider bisphosphonates if T-score ≤-2.5 or fragility fractures occur

Renal and Genitourinary Anomalies

Structural renal anomalies occur in 30-40% of individuals with TS, including:

Horseshoe kidney (most common)
Renal ectopia or malrotation
Duplicated collecting systems
Absent or hypoplastic kidney

These anomalies increase risk of urinary tract infections, nephrolithiasis, and hypertension. Renal ultrasound should be performed at diagnosis and repeated if symptoms develop.

Clinical Pearl: Even with normal renal anatomy, women with TS demonstrate increased susceptibility to urinary tract infections. Maintain low threshold for investigating urinary symptoms and consider prophylactic strategies in patients with recurrent infections.

Reproductive Considerations and Fertility

Spontaneous Fertility

Approximately 5-10% of women with TS achieve spontaneous pregnancy, more commonly in those with mosaic karyotypes. However, spontaneous pregnancies carry substantial risks:

30-40% miscarriage rate
Increased chromosomal abnormalities in offspring
Maternal cardiovascular complications, including aortic dissection

Assisted Reproductive Technology

Oocyte donation represents the primary fertility option for most women with TS, with pregnancy rates comparable to recipients without TS. However, pregnancy in TS carries significant maternal mortality risk (2%), primarily from aortic dissection and cardiac complications.

Contemporary Pregnancy Counseling:

Pre-pregnancy assessment must include:

Comprehensive cardiovascular evaluation including cardiac MRI
ASI calculation—pregnancy generally contraindicated if ASI >2.0-2.2 cm/m²
Optimization of blood pressure control
Multidisciplinary discussion involving cardiology, maternal-fetal medicine, and genetics

Even with normal cardiac assessment, pregnancies require:

First-trimester cardiac MRI to establish baseline
Monthly cardiovascular monitoring throughout pregnancy
Beta-blocker prophylaxis to reduce aortic wall stress
Careful blood pressure management
Planned delivery via cesarean section at tertiary centers with cardiac surgery capabilities

The "Oyster": Spontaneous pregnancy in women with undiagnosed TS represents a particularly dangerous scenario. Consider TS screening in any short-statured woman with primary amenorrhea or premature ovarian failure who presents pregnant, and ensure urgent comprehensive cardiovascular assessment.

Fertility Preservation

For adolescents and young adults with TS who retain ovarian function (15-30%), ovarian tissue cryopreservation or oocyte cryopreservation represents emerging options, though success rates remain limited and variable.

Otolaryngologic Manifestations

Hearing loss affects 60-90% of adults with TS, progressing with age:

Sensorineural hearing loss: 20-60%, often beginning in childhood
Conductive hearing loss: 30-60%, frequently related to recurrent otitis media
Mixed hearing loss: common in adults

Annual audiometry is recommended, with hearing aids fitted as needed. Recurrent otitis media in childhood may benefit from tympanostomy tube placement.

Hepatic Complications

Beyond NAFLD, women with TS demonstrate increased risk of:

Elevated transaminases (40-80% of adults)
Nodular regenerative hyperplasia
Hepatic steatosis
Cirrhosis (rare but reported)

The etiology remains incompletely understood, potentially involving hormonal factors, metabolic abnormalities, and intrinsic hepatic vulnerability. Management focuses on addressing modifiable risk factors (obesity, metabolic syndrome) and surveillance for progressive disease.

Gastrointestinal and Autoimmune Considerations

Inflammatory bowel disease, particularly Crohn's disease, occurs with 2-3 fold increased frequency in TS. Celiac disease affects 2-6% of women with TS, compared to 1% in the general population.

Screening Recommendation: Consider screening for celiac disease with tissue transglutaminase antibodies, particularly if gastrointestinal symptoms, iron deficiency, or low bone density present. Maintain clinical suspicion for IBD in patients with chronic diarrhea or abdominal pain.

Neurocognitive and Psychosocial Aspects

Cognitive Profile

Intelligence generally falls within normal range, but specific neurocognitive patterns emerge:

Visuospatial processing deficits (60-70%)
Executive function difficulties
Mathematics challenges
Social cognition impairments

Verbal abilities typically remain intact or superior.

Psychosocial Challenges

Increased rates of anxiety disorders (25-40%), depression (20-30%), and attention deficit disorders (20-25%) necessitate screening and appropriate referral. Social difficulties and reduced quality of life measures underscore the importance of psychological support.

Management Hack: Screen annually for anxiety and depression using validated instruments (PHQ-9, GAD-7). Women with TS benefit from early intervention, and group support programs connecting individuals with TS demonstrate improved psychosocial outcomes.

Contemporary Management: An Integrated Approach

The Multidisciplinary Team

Optimal TS care requires coordination among:

Internal medicine/primary care
Cardiology
Endocrinology
Gynecology/reproductive endocrinology
Genetics
Audiology
Psychology/psychiatry
Additional specialists as needed

Annual Comprehensive Assessment Template

A systematic annual evaluation should include:

Cardiovascular: Blood pressure measurement, cardiac symptoms assessment, imaging per protocol

Endocrine: Assessment of HRT adherence and side effects, metabolic screening (glucose, lipids, liver function), thyroid function

Reproductive: Menstrual history, contraception discussion, fertility desires

Audiology: Hearing assessment

Bone Health: Fracture history, DEXA scan per protocol

Psychosocial: Mental health screening, quality of life assessment

General Health: Cancer screening per general population guidelines, age-appropriate immunizations

Emerging Therapies and Future Directions

Several investigational approaches show promise:

Pharmacological Aortic Protection: Beyond beta-blockers, investigation of angiotensin receptor blockers and potentially newer agents targeting TGF-β signaling in aortopathy

Growth Enhancement: Long-acting growth hormone preparations and combination therapies with IGF-1 for children

Fertility Preservation: Advances in ovarian tissue transplantation and in vitro maturation techniques

Gene Therapy: Early-stage research exploring potential interventions, though significant challenges remain

Key Clinical Pearls and Practice Points

Calculate ASI, not just aortic diameter: Body surface area-indexed measurements provide more accurate risk stratification
Image the entire aorta: Echocardiography alone misses critical pathology in the aortic arch and descending aorta
Emphasize HRT adherence: Cardiovascular and bone health benefits extend beyond reproductive considerations
Think beyond the diagnosis: Women with TS experience the same adult health issues as the general population—don't attribute all symptoms to TS
Facilitate social connections: Support groups and online communities significantly improve quality of life
Pregnancy counseling starts early: Fertility discussions should occur well before conception desires arise, allowing adequate assessment and planning
Maintain lifelong cardiovascular surveillance: Risk doesn't diminish with age; dissection can occur decades after normal imaging
Coordinate care: Establish clear communication pathways among specialists and with the patient
Empower patients: Education about their condition enables informed decision-making and promotes self-advocacy
Consider the whole person: Address psychosocial aspects alongside medical complications for optimal outcomes

Conclusion

Turner syndrome represents a complex, multisystem condition requiring sophisticated medical management throughout the lifespan. As survival improves and women with TS increasingly receive care within internal medicine practices, physicians must develop comprehensive knowledge of the condition's natural history, evidence-based screening protocols, and contemporary management strategies.

The three-fold increased mortality risk—driven primarily by cardiovascular complications—demands vigilant surveillance and proactive intervention. Optimization of endocrine, metabolic, reproductive, and psychosocial health requires individualized, patient-centered approaches within a multidisciplinary framework.

Future advances in genetic understanding, targeted therapeutics, and assisted reproductive technologies hold promise for further improving outcomes. However, the foundation of excellent TS care rests on thorough clinical assessment, evidence-based screening, early intervention for complications, and compassionate, continuous engagement with patients navigating this lifelong condition.

References

Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017;177(3):G1-G70.
Trolle C, Mortensen KH, Hjerrild BE, et al. Clinical care of adult Turner syndrome—new aspects. Pediatr Endocrinol Rev. 2012;9 Suppl 2:739-749.
Mortensen KH, Andersen NH, Gravholt CH. Cardiovascular phenotype in Turner syndrome—integrating cardiology, genetics, and endocrinology. Endocr Rev. 2012;33(5):677-714.
Sybert VP, McCauley E. Turner's syndrome. N Engl J Med. 2004;351(12):1227-1238.
Bondy CA; Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007;92(1):10-25.
Schoemaker MJ, Swerdlow AJ, Higgins CD, et al. Mortality in women with turner syndrome in Great Britain: a national cohort study. J Clin Endocrinol Metab. 2008;93(12):4735-4742.
Carlson M, Silberbach M. Dissection of the aorta in Turner syndrome: two cases and review of 85 cases in the literature. J Med Genet. 2007;44(12):745-749.
Hjerrild BE, Mortensen KH, Gravholt CH. Turner syndrome and clinical treatment. Br Med Bull. 2008;86:77-93.
Ostberg JE, Storry C, Donald AE, et al. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism. Clin Endocrinol (Oxf). 2007;66(4):557-564.
Landin-Wilhelmsen K, Bryman I, Windh M, Wilhelmsen L. Osteoporosis and fractures in Turner syndrome-importance of growth promoting and oestrogen therapy. Clin Endocrinol (Oxf). 1999;51(4):497-502.
Bernard V, Donadille B, Zenaty D, et al. Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome. Hum Reprod. 2016;31(4):782-788.
Chevalier N, Letur H, Lelannou D, et al. Materno-fetal cardiovascular complications in Turner syndrome after oocyte donation: insufficient prepregnancy screening and pregnancy follow-up are associated with poor outcome. J Clin Endocrinol Metab. 2011;96(2):E260-E267.
Hagman A, Loft A, Wennerholm UB, et al. Obstetric and neonatal outcome after oocyte donation in 106 women with Turner syndrome: a Nordic cohort study. Hum Reprod. 2013;28(6):1598-1609.
Ross J, Roeltgen D, Zinn A. Cognition and the sex chromosomes: studies in Turner syndrome. Horm Res. 2006;65(1):47-56.
Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol. 1998;51(2):147-158.

Word count: 3,987 words

Disclosure Statement: The author has no conflicts of interest to declare.

Acknowledgments: This review synthesizes evidence-based recommendations from international guidelines and contemporary literature to provide practical guidance for internal medicine practitioners caring for adults with Turner syndrome.